post-hoc subgroup analysis from pacific: durvalumab after crt in unresectable stage iii egfrm nsclc
Published 2 years ago • 173 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
6:22
refining which patients benefit from consolidation durvalumab for stage iii unresectable nsclc
-
1:50
consolidation therapy for unresectable stage iii egfr-mutant nsclc
-
3:25
pacific 6: durvalumab after scrt in patients with nsclc
-
2:14
pacific-6: durvalumab after chemoradiotherapy in unresectable stage iii nsclc | crsf
-
1:07
pacific trial updates: durvalumab after chemotherapy in nsclc
-
![[lung]the role of durvalumab in patients with stage 3 lung cancer in a real hospital](https://i.ytimg.com/vi/EwpYIgllxqY/mqdefault.jpg)
3:53
[lung]the role of durvalumab in patients with stage 3 lung cancer in a real hospital
-
6:48
durvalumab improves pfs in stage iii lung cancer
-
3:25
impact of radiation dose to immune cells in unresectable or stage iii nsclc in the durvalumab era
-
4:43
treating for stage iii nsclc after progression on durvalumab
-
3:31
expert comment: caspian trial of durvalumab in sclc | raffaele califano
-
3:39
results from the pacific study: durvalumab with chemoradiation for the treatment of nsclc
-
3:59
pacific trial of durvalumab for stage iii nsclc
-
1:54
dr. gainor on the pacific-2 trial in stage iii nsclc
-
1:06
phase iii real-world pacific-r trial for nsclc
-
1:13
phase ii study of durvalumab for patients with nsclc
-
0:45
what is stage 1b lung cancer?
-
4:46
5-year survival outcomes from the pacific trial
-
6:07
four chemo cycles given with durvalumab ± tremelimumab optimise response in patients with mnsclc